Acrylamido Derivatives Inhibit MPTP Opening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with mitochondrial permeability transition pore (MPTP) activity, such as ischemia/reperfusion damage and neurodegenerative diseases, are limited by the use of large, complex molecules like cyclosporine-A analogues, which have restricted efficacy due to their pharmacological modulation of cyclophilin-D and potential cytotoxicity at higher doses.
Innovation Solution
Development of acrylamido compounds with potent MPTP inhibitory activity, specifically designed to target the MPTP, offering a more effective and safer alternative for preventing or treating MPTP-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cyclosporine-A analogues are used to inhibit MPTP, then MPTP inhibitory activity is achieved, but the molecules are large and complex with restricted efficacy and potential cytotoxicity
Solution Approach 1:
The patent creates simplified copy structures that replicate the essential MPTP inhibitory function of cyclosporine-A without requiring the full complex molecular structure. The acrylamido compounds (I) are designed as smaller analogues that copy the key pharmacophore elements needed for MPTP inhibition while eliminating unnecessary complexity
Solution Approach 2:
The invention replaces expensive, complex cyclosporine-A molecules with simpler, more economically viable acrylamido compounds. These smaller molecules achieve the same therapeutic effect with reduced molecular weight and simplified structure, making them more accessible and potentially safer for clinical use
2Reliability
If cyclosporine-A analogues are used to inhibit MPTP, then MPTP inhibitory activity is achieved, but cytotoxicity increases at higher doses
Solution Approach 1:
The patent creates copy structures that replicate only the essential MPTP inhibitory function without the cytotoxic side effects. The acrylamido compounds (I) are designed to copy the pharmacophore elements responsible for MPTP binding while eliminating structural features that cause cytotoxicity at higher doses
Solution Approach 2:
The invention extracts and isolates the specific pharmacophore elements from cyclosporine-A that are responsible for MPTP inhibition, separating them from the portions of the molecule that cause cytotoxicity. This allows for selective retention of beneficial effects while removal of harmful properties
Data Source
AI summary
Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R', R", W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.